According to the latest filing submitted to the U.S. Securities and Exchange Commission (SEC), a lawsuit accuses biotechnology company Ocular Therapeutix of spreading false information about EyePoint and its product Duravyu.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
The AI arms race drives up financing costs: US tech companies’ financing premium hits the highest level since 2003
The average bond financing cost premium for US investment-grade technology company borrowers, compared to the overall US market, has reached its highest level since 2003. Analysts point out that as financing supply continues to expand, the spread on US technology bonds may widen further. US technology companies are seeking to diversify their massive funding needs through different currencies and markets. BNP Paribas expects the net supply of investment-grade corporate bonds in the Eurozone to increase by 83% by 2027.
Crypto prices
More
